Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor-Reference-Cited by-同舟云学术

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

Published:2011 Issue:6 Volume:13 Page:R209
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Kobie James J,Zheng Bo,Bryk Peter,Barnes Michael,Ritchlin Christopher T,Tabechian Darren A,Anandarajah Allen P,Looney R,Thiele Ralf G,Anolik Jennifer H,Coca Andreea,Wei Chungwen,Rosenberg Alexander F,Feng Changyong,Treanor John J,Lee F Eun-Hyung,Sanz Ignacio

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference27 articles.

1. The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

2. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

3. Tumor necrosis factor blockade and the risk of viral infection

4. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

5. Methotrexate—how does it really work?

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Panel Consensus Statements on Vaccination for Adults with AIRD in India;Indian Journal of Rheumatology;2024-09-04

2. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy;Journal of Allergy and Clinical Immunology;2024-09

3. Anti-Tumour Necrosis Factor and New Paradigms for Therapies Using Antibodies;Molecular Biology of B Cells;2024

4. Limited antibody response after BA.4‐5 adapted booster vaccination in rheumatic patients receiving anti‐TNF therapy: Results of a case series;Journal of Medical Virology;2023-12

5. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study;eClinicalMedicine;2023-10